MaxCyte (NASDAQ:MXCT) Stock Rating Lowered by Wall Street Zen

MaxCyte (NASDAQ:MXCT) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $7.00.

MaxCyte Stock Performance

NASDAQ MXCT opened at $1.43 on Friday. The firm has a 50 day simple moving average of $1.57 and a 200-day simple moving average of $1.68. MaxCyte has a one year low of $1.26 and a one year high of $5.20. The firm has a market cap of $152.54 million, a price-to-earnings ratio of -3.25 and a beta of 1.22.

MaxCyte (NASDAQ:MXCT) last announced its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The business had revenue of $6.41 million for the quarter, compared to analysts’ expectations of $8.37 million. MaxCyte had a negative return on equity of 23.50% and a negative net margin of 132.57%. Equities analysts predict that MaxCyte will post -0.42 EPS for the current fiscal year.

Institutional Trading of MaxCyte

A number of institutional investors have recently bought and sold shares of the business. Farther Finance Advisors LLC increased its holdings in shares of MaxCyte by 7,935.4% in the 2nd quarter. Farther Finance Advisors LLC now owns 11,812 shares of the company’s stock valued at $26,000 after acquiring an additional 11,665 shares during the last quarter. CWM LLC lifted its stake in MaxCyte by 92.7% during the second quarter. CWM LLC now owns 12,132 shares of the company’s stock worth $26,000 after purchasing an additional 5,836 shares during the last quarter. Prudential Financial Inc. acquired a new position in MaxCyte in the second quarter valued at approximately $26,000. May Hill Capital LLC purchased a new position in MaxCyte in the second quarter valued at approximately $27,000. Finally, State of Wyoming purchased a new position in MaxCyte in the second quarter valued at approximately $38,000. 68.81% of the stock is owned by hedge funds and other institutional investors.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.